Clinical Trial: Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971198) titled 'Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation' on May 06.

Brief Summary: To evaluate the safety, tolerability and pharmacokinetic characteristics of HSK39004 dry powder inhalation in healthy subjects.

Study Start Date: Feb. 10

Study Type: INTERVENTIONAL

Condition: Healthy Volunteers

Intervention: DRUG: HSK39004

0.75~4mg

DRUG: Placebo

0.75~4mg

Recruitment Status: COMPLETED

Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Disclaimer: Curated by HT Syndication....